1. The core principle is that **damaged or dying cardiac cells release their intracellular enzymes and proteins into the bloodstream**, so measuring these biomarkers in blood indirectly detects myocardial injury.
2. An ideal diagnostic marker
should be **cardiac-specific, released early, rise and fall in a predictable
pattern, remain detectable long enough, and be easy to measure accurately**.
3. **Cardiac troponins (cTnI
and cTnT)** are the preferred markers because they are largely unique to heart
muscle, giving them very high specificity for myocardial damage.
4. Diagnosis relies on
**kinetics**—each marker has a characteristic rise, peak, and return to
baseline, so the timing of the blood draw relative to symptom onset matters
greatly.
5. Because a single value can
be misleading, **serial measurements** (repeat testing over hours) are used to
detect a significant rise or fall (delta change), which helps distinguish acute
injury from chronic elevation.
6. **High-sensitivity troponin
assays** allow rapid rule-in/rule-out protocols by detecting tiny amounts of
the marker very early after injury.
7. **CK-MB**, with its shorter
half-life and faster normalization, remains useful for detecting **re-infarction**,
since a new rise can be identified after a previous infarct.
8. Enzyme results must always
be interpreted **together with clinical symptoms, ECG changes, and imaging**,
because elevated markers alone do not prove that the injury is due to an acute
coronary thrombosis.

0 Comments